Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-12-03
2009-08-04
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266300, C544S286000
Reexamination Certificate
active
07569578
ABSTRACT:
The present invention relates to compounds of Formula (I)as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
REFERENCES:
patent: 6313097 (2001-11-01), Eberlein et al.
patent: 6344449 (2002-02-01), Rudolf et al.
patent: 6521609 (2003-02-01), Doods et al.
patent: 6552043 (2003-04-01), Patchett et al.
patent: 2001/0036946 (2001-11-01), Rudolf et al.
patent: 2003/0139417 (2003-07-01), Eberlein et al.
patent: 2003/0181462 (2003-09-01), Doods et al.
patent: 2003/0191068 (2003-10-01), Trunk et al.
patent: 2003/0212057 (2003-11-01), Rudolf et al.
patent: 2003/0236282 (2003-12-01), Hurnaus et al.
patent: 2004/0014679 (2004-01-01), Trunk et al.
patent: 2004/0063735 (2004-04-01), Chaturvedula et al.
patent: 2004/0076587 (2004-04-01), Kruss et al.
patent: 2004/0132716 (2004-07-01), Rudolf et al.
patent: 2004/0192729 (2004-09-01), Rudolf et al.
patent: 2004/0204397 (2004-10-01), Chaturvedula et al.
patent: 2004/0214819 (2004-10-01), Rudolf et al.
patent: 2004/0229861 (2004-11-01), Burgey et al.
patent: 2004/0248816 (2004-12-01), Doods et al.
patent: 2005/0032783 (2005-02-01), Doods et al.
patent: 2005/0065094 (2005-03-01), Davidai
patent: 2005/0215546 (2005-09-01), Hurnaus et al.
patent: 2005/0215576 (2005-09-01), Degnan et al.
patent: 2005/0227968 (2005-10-01), Lustenberger et al.
patent: 2005/0233980 (2005-10-01), Doods
patent: 2005/0234054 (2005-10-01), Mueller et al.
patent: 2005/0234067 (2005-10-01), Mueller et al.
patent: 2005/0250763 (2005-11-01), Mueller et al.
patent: 2005/0256098 (2005-11-01), Burgey et al.
patent: 2005/0256099 (2005-11-01), Mueller et al.
patent: 2005/0272955 (2005-12-01), Zimmer et al.
patent: 2006/0094707 (2006-05-01), Chaturvedula et al.
patent: 2 387 613 (2001-05-01), None
patent: 2503455 (2005-04-01), None
patent: 1 227 090 (2002-07-01), None
patent: WO 97/09046 (1997-03-01), None
patent: WO 98/09630 (1998-03-01), None
patent: WO 98/11128 (1998-03-01), None
patent: WO 98/56779 (1998-12-01), None
patent: WO 99/52875 (1999-10-01), None
patent: WO 00/18764 (2000-04-01), None
patent: WO 00/55154 (2000-09-01), None
patent: WO 01/32648 (2001-03-01), None
patent: WO 01/32649 (2001-03-01), None
patent: WO 01/25228 (2001-04-01), None
patent: WO 01/49676 (2001-07-01), None
patent: WO 02/10140 (2002-02-01), None
patent: WO 03/027252 (2003-04-01), None
patent: WO 03/070753 (2003-08-01), None
patent: WO 03/076432 (2003-09-01), None
patent: WO 03/104236 (2003-12-01), None
patent: WO 2004/037810 (2004-05-01), None
patent: WO 2004/082602 (2004-09-01), None
patent: WO 2004/082605 (2004-09-01), None
patent: WO 2004/082678 (2004-09-01), None
patent: WO 2004/083187 (2004-09-01), None
patent: WO 2004/087649 (2004-10-01), None
patent: WO 2004/091514 (2004-10-01), None
patent: WO 2004/092166 (2004-10-01), None
patent: WO 2004/092168 (2004-10-01), None
patent: WO 2005/000807 (2005-01-01), None
patent: WO 2005/009962 (2005-02-01), None
patent: WO 2005/013894 (2005-02-01), None
patent: WO 2005/056550 (2005-06-01), None
patent: WO2005/065779 (2005-07-01), None
patent: WO 2005/072308 (2005-08-01), None
patent: WO2005/084672 (2005-09-01), None
patent: WO 2005/092880 (2005-10-01), None
patent: WO 2005/095383 (2005-10-01), None
patent: WO 2005/100343 (2005-10-01), None
patent: WO 2005/100352 (2005-10-01), None
patent: WO/2005/100360 (2005-10-01), None
patent: WO 2005/102322 (2005-11-01), None
patent: WO 2005/103037 (2005-11-01), None
patent: WO 2005/121078 (2005-12-01), None
patent: WO 2006/052378 (2006-05-01), None
patent: WO 2006/060678 (2006-06-01), None
Ashina, M. et al., “Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks”,Pain, 2000, 86(1-2):133-138.
Brain, S.D. et al., “CGRP receptors: a headache to study, but will antagonists prove therapeutic in migraine?”,TiPS, 2002, 23(2): 51-53.
Edvinsson, L., “Calcitonin Gene-Related Peptide (CGRP) and the Pathophysiology of Headache”,CNS Drugs, 2001, 15(10):745-753.
Evans, B.N. et al., “CGRP-RCP, a Novel Protein Required for Signal Transduction at Calcitonin Gene-related Peptide and Adrenomedullin Receptors”,J. Biol. Chem. 2000, 275(4): 31438-31443.
Gallai, V. et al. “Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed byoth interictally and ictally”,Cephalalgia1995;15: 384-390.
Goadsby, P.J. et al., “Vasoactive peptide release in the extracerebral circulation of humans during migrain headache”.Annals of Neurology, 1990, 28(2):183-187.
Grant, A.D., “Evidence of a role for NK, and CGRP receptors in mediating neurogenic vasodilatation in the mouse ear”,Brit. J. Pharmacol. 2002, 135: 356-362.
Juaneda, C. et al. “The molecular pharmacology of CGRP and related peptide receptor subtypes”,TiPS, 2000, 21: 432-438.
Lassen, L.H. et al. “CGRP may play a causative role in migraine”,Cephalalgia, 2002 22(1): 54-61.
Mallee, J.J. et al. “Receptor Activity-modifying Protein 1 Determines the Species Selectivity of Non-peptide CGRP Receptor Antagonist”,J., Biol. Chem., 2002, 277(16): 14294-14298.
McLatchie, L.M. et al., “RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor”,Nature, 1998, 393: 333-339.
Olesen, J. et al., “Calcitonin Gene-Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine”,New England J. of Medicine, 2004, 350 (11): 1104-1110.
Poyner, D.R. et al., “Pharmacological characterization of a receptor for calcitonin gene-related peptide on rat, L6 myocytes”,Brit. J. of Pharm., 1992, 105: 441-447.
Rosenfeld, et al., “Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing”,Nature, 1983, 304:129-135.
Shen, Y-T. et al., “Functional Role of α-Calcitonin Gene-Related Peptide in the Regulation of the Cardiovascular System”,J. Pharm. Exp. Ther., 2001, 298:551-558.
Van Valen, F. et al., “Calcitonin gene-related peptide (CGRP) receptors are linked to cyclic adenosine monophosphate production in SK-N-MC human neuroblastoma cells”,Neuroscience Letters, 1990, 119: 195-198.
Williamson, D.J. and Hargreaves, R.J., “Neurogenic Inflammation in the Context of Migraine”,Microsc. Res. Tech., 2001, 53: 167-178.
U.S. Appl. No. 11/091,429, filed Mar. 28, 2005, Degnan, et al., (copending application).
U.S. Appl. No. 60/624,655, filed Nov. 3, 2004, Chaturvedula, et al.
U.S. Appl. No. 60/678,099, filed May 5, 2005, Chaturvedula, et al.
U.S. Appl. No. 60/633,159, filed Dec. 3, 2004, Chaturvedula, et al.
Chu, et al., “The calcitonin gene-related peptide (CGRP) antagonist CGRP8-37 block vasodilatation in inflammed rat skin: involvement of adrenomedullin in addition to CGRP,”Neuroscience Letters, 310, 2001, 169-172.
De Vries, et al., “Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy,”European Journal of Pharmacology, 375, 1999, 61-74.
Doods, et al., “Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist,”British Journal of Pharmacology, 2000, 129, 420-423.
Escott, et al., “Effect of a calcitonin gene-related peptide antagonist (CGRP8-37) on skin vasodilatation and oedema induced by stimulation of the rat saphenous nerve”,British Journal of Pharmacology, 1993, 100, 772-776.
Escott, et al., “Trigeminal ganglion stimulation increases facial skin blood flow in the
Chaturvedula Prasad V.
Chen Ling
Degnan Andrew P.
Dubowchik Gene M.
Luo Guanglin
Bristol-Meyers Squibb Company
Epperson James
Makujina Shah R.
Truong Tamthom N
Wilson James O
LandOfFree
Heterocyclic anti-migraine agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic anti-migraine agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic anti-migraine agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4090509